JP2000502443A - 毛管電気泳動を使用して新規の治療コンパウンド類のための天然物サンプルのスクリーニング - Google Patents
毛管電気泳動を使用して新規の治療コンパウンド類のための天然物サンプルのスクリーニングInfo
- Publication number
- JP2000502443A JP2000502443A JP09522198A JP52219897A JP2000502443A JP 2000502443 A JP2000502443 A JP 2000502443A JP 09522198 A JP09522198 A JP 09522198A JP 52219897 A JP52219897 A JP 52219897A JP 2000502443 A JP2000502443 A JP 2000502443A
- Authority
- JP
- Japan
- Prior art keywords
- sample
- target molecule
- capillary electrophoresis
- binding
- complex biological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 89
- 238000005251 capillar electrophoresis Methods 0.000 title claims abstract description 80
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 24
- 238000012216 screening Methods 0.000 title description 20
- 229930014626 natural product Natural products 0.000 title description 16
- 238000000034 method Methods 0.000 claims abstract description 171
- 239000003446 ligand Substances 0.000 claims abstract description 107
- 230000027455 binding Effects 0.000 claims abstract description 60
- 238000009739 binding Methods 0.000 claims abstract description 60
- 230000033001 locomotion Effects 0.000 claims abstract description 37
- 238000001962 electrophoresis Methods 0.000 claims abstract description 19
- 238000012544 monitoring process Methods 0.000 claims abstract description 9
- 239000012620 biological material Substances 0.000 claims description 50
- 238000001514 detection method Methods 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 239000000872 buffer Substances 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 108090000209 Carbonic anhydrases Proteins 0.000 claims description 15
- 102000003846 Carbonic anhydrases Human genes 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 12
- 239000002131 composite material Substances 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 235000010633 broth Nutrition 0.000 claims description 7
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 claims description 7
- 239000012087 reference standard solution Substances 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108010010369 HIV Protease Proteins 0.000 claims description 3
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 102000001253 Protein Kinase Human genes 0.000 claims description 3
- 238000004141 dimensional analysis Methods 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 108060006633 protein kinase Proteins 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 2
- 229960003766 thrombin (human) Drugs 0.000 claims description 2
- 239000012491 analyte Substances 0.000 claims 2
- 238000002474 experimental method Methods 0.000 abstract description 9
- 230000007935 neutral effect Effects 0.000 abstract description 9
- 230000008859 change Effects 0.000 abstract description 8
- 230000002452 interceptive effect Effects 0.000 abstract description 5
- 239000000287 crude extract Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 98
- 108090000190 Thrombin Proteins 0.000 description 31
- 229960004072 thrombin Drugs 0.000 description 30
- 239000000203 mixture Substances 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 102000007625 Hirudins Human genes 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 229940006607 hirudin Drugs 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 108010007267 Hirudins Proteins 0.000 description 13
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 13
- 238000001914 filtration Methods 0.000 description 12
- 108010090804 Streptavidin Proteins 0.000 description 10
- 229960002685 biotin Drugs 0.000 description 9
- 235000020958 biotin Nutrition 0.000 description 9
- 239000011616 biotin Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 108091023037 Aptamer Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000002860 competitive effect Effects 0.000 description 7
- 238000000159 protein binding assay Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000005684 electric field Effects 0.000 description 6
- 241000186361 Actinobacteria <class> Species 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- -1 well sides Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000005350 fused silica glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000000874 microwave-assisted extraction Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
- OZXIZRZFGJZWBF-UHFFFAOYSA-N 1,3,5-trimethyl-2-(2,4,6-trimethylphenoxy)benzene Chemical compound CC1=CC(C)=CC(C)=C1OC1=C(C)C=C(C)C=C1C OZXIZRZFGJZWBF-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 101150035093 AMPD gene Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 238000001386 capillary affinity electrophoresis Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- MOOGIHKPTRJVRV-ZHVXJWHRSA-N chembl1814697 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(N)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(N)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(N)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COC(=O)CCCC[C@H]2[C@H]3NC(=O)N[C@H]3CS2)[C@@H](OP(N)(=O)OC[C@H]2O[C@H]([C@H](OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C(NC(=O)C(C)=C3)=O)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)OP(N)(=O)OC[C@@H]3[C@H](C[C@@H](O3)N3C4=C(C(NC(N)=N4)=O)N=C3)O)C2)N2C3=C(C(NC(N)=N3)=O)N=C2)C1 MOOGIHKPTRJVRV-ZHVXJWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004185 countercurrent chromatography Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000011499 joint compound Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- SHOJXDKTYKFBRD-UHFFFAOYSA-N mesityl oxide Natural products CC(C)=CC(C)=O SHOJXDKTYKFBRD-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- GOMLCFUVZKLQCO-HTLAMOOLSA-N thrombin aptamer Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)[C@@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 GOMLCFUVZKLQCO-HTLAMOOLSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G01N33/561—Immunoelectrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 複合生物物質から未知の活性化合物を選別する方法であって、 複合生物物質の試料を供給する工程と、 前記複合生物物質の試料を目標分子に結合する工程と、 前記結合する工程からの試料を毛管電気泳動装置内に注入する工程と、 前記結合する工程からの前記試料を毛管電気泳動に導入する工程と、 前記毛管電気泳動による前記目標分子の移動を監視する工程と を備えることを特徴とする方法。 2. 請求項1の方法において、 前記目標分子の移動が、前記複合生物物質の試料中に活性化合物の存在を示 しているか否かを決定する工程と、 前記決定する工程で示された活性化合物を前記複合生物物質の試料から分離 し、そして前記化合物の活性を試験する工程とを更に備えることを特徴とする方 法。 3. 請求項1の方法において、 前記毛管電気泳動による前記目標分子の移動を、参照標準液の移動と比較す る工程を更に備えることを特徴とする方法。 4. 請求項3の方法において、 前記監視する工程は、前記目標分子を追跡する工程を備え、 前記参照標準液は、前記比較する工程において、前記目標分子を備えること を特徴とする方法。 5. 請求項3の方法において、 前記結合する工程は、前記目標分子の既知の配位子を前記複合生物物質の試 料および前記目標分子に結合する工程を更に備え、 前記監視する工程は、前記既知の配位子を追跡する工程を備え、 前記参照標準液は、前記比較する工程において、前記既知の配位子と前記目 標分子の組み合わせを備える ことを特徴とする方法。 6. 請求項3の方法において、 前記目標分子の既知の配位子は、前記導入する工程において、前記毛管電気 泳動を遂行するための運用緩衝液内に存在し、 前記監視する工程は、前記目標分子を追跡する工程を備え、 前記参照標準液は、前記比較する工程において、前記既知の配位子と前記目 標分子の組み合わせを備える ことを特徴とする方法。 7. 請求項1の方法において、 前記毛管電気泳動装置は、複数の毛管を備えることを特徴とする方法。 8. 請求項1の方法において、 前記毛管電気泳動装置は、微小組立技術によって形成されたデバイス上に複 数のチャネルを備えることを特徴とする方法。 9. 請求項1の方法において、 1以上の目標分子は、前記結合する工程において、前記試料に結合されてい ることを特徴とする方法。 10. 請求項1の方法において、 前記目標分子の移動は、UV吸収の検出によって監視されることを特徴とす る方法。 11. 請求項1の方法において、 前記目標分子の移動は、レーザ誘導蛍光の検出によって監視されることを特 徴とする方法。 12. 請求項1の方法において、 前記試料は、前記供給する工程において、1以上のソースからの複合生物物 質を備えることを特徴とする方法。 13. 請求項1の方法において、 前記複合生物物質は、前記供給する工程に先行して、前処理されていること を特徴とする方法。 14. 請求項1の方法において、 前記毛管電気泳動装置は、分析デバイスに直接接続されていることを特徴と する方法。 15. 請求項14の方法において、 前記分析デバイスは、質量分析器であることを特徴とする方法。 16. 請求項8の方法において、 前記微小組立技術によって形成されたデバイスは、2次元分析用に構成され ていることを特徴とする方法。 17. 請求項1の方法において、 前記複合生物物質は、地上の植物の抽出物、海中の植物の抽出物、海中の有 機体の抽出物、微生物のブイヨン、および微生物の抽出物からなる群から選択さ れたものであることを特徴とする方法。 18. 請求項1の方法において、 前記複合生物物質は、組み合わせ可能なライブラリであることを特徴とする 方法。 19. 請求項1の方法において、 前記目標分子は、炭酸脱水酵素、HIV反転転写酵素、HIVプロテアーゼ 、ヒト・トロンビン、タンパク質キナーゼ、および治療用タンパク質の活性ペプ チドドメインからなる群から選択されたものであることを特徴とする方法。 20. 請求項5または6の方法において、 前記既知の配位子は、ペプチドおよびその類似物、オリゴヌクレオチドおよ びその類似物、金属、および荷電された微小分子からなる群から選択されたもの であることを特徴とする方法。 21 請求項4、5または8のいずれかの方法において、 前記追跡される分子は、前記監視する工程において、純粋に正の電荷を有し ていることを特徴とする方法。 22. 複合生物物質から未知の活性化合物を選別する方法であって、 複合生物物質の試料を供給する工程と、 前記複合生物物質の試料を目標分子に結合し、続けて前記目標物質の既知の 配位子に結合する工程と、 前記結合する工程からの試料を毛管電気泳動装置内に注入する工程と、 前記結合する工程からの前記試料を毛管電気泳動に導入する工程と、 前記毛管電気泳動による前記目標分子の移動を監視する工程と 前記毛管電気泳動による前記目標分子の移動を、参照標準液の移動と比較す る工程とを備え、 前記参照標準液は、前記既知の配位子と前記目標分子の組み合わせを備える ことを特徴とする方法。 23. 請求項22の方法において、 前記参照標準液の移動と比較された前記目標分子の移動が、前記複合生物物 質の試料中に活性化合物の存在を示しているか否かを決定する工程と、 前記決定する工程で示された活性化合物を前記複合生物物質の試料から分離 し、そして前記化合物の活性を試験する工程とを更に備えることを特徴とする方 法。 24. 複合生物物質から未知の活性化合物を選別する方法であって、 複合生物物質の試料を供給する工程と、 前記複合生物物質の試料を目標分子に結合する工程と、 前記結合する工程からの試料を毛管電気泳動装置内に注入する工程と、 前記結合する工程からの前記試料を毛管電気泳動に導入する工程と、 前記毛管電気泳動による前記目標分子の移動を監視する工程と 前記毛管電気泳動による前記目標分子の移動を、参照標準液の移動と比較す る工程とを備え、 前記毛管電気泳動を遂行するための運用緩衝液は、前記目標分子の既知の配 位子を備え、 前記参照標準液は、前記既知の配位子と前記目標分子の組み合わせを備える ことを特徴とする方法。 25. 請求項24の方法において、 前記参照標準液の移動と比較された前記目標分子の移動が、前記複合生物物 質の試料中に活性化合物の存在を示しているか否かを決定する工程と、 前記決定する工程で示された活性化合物を前記複合生物物質の試料から分離 し、そして前記化合物の活性を試験する工程とを更に備えることを特徴とする方 法。 26. 複合生物物質から未知の活性化合物を選別する方法であって、 複合生物物質の第1の試料を供給する工程と、 複合生物物質の前記第1の試料を毛管電気泳動装置内に注入する工程と、 複合生物物質の前記第1の試料を毛管電気泳動に導入する工程と、 前記第1の試料の毛管電気泳動に後続し、複合生物物質の前記第1の試料に 由来する化合物の存在を検出し、そして検出された化合物の第1の検出パターン を生成する一般的な検出方法を使用する工程と、 複合生物物質の第2の試料を供給する工程と、 目標分子の第2の組み合わせ試料を形成するために、複合生物物質の前記第 2の試料を目標分子に結合させる工程と、 前記結合させる工程からの前記組み合わせ試料を毛管電気泳動装置内に注入 する工程と、 前記結合させる工程からの前記組み合わせ試料を毛管電気泳動に導入する工 程と、 前記結合させる工程からの前記組み合わせ試料の毛管電気泳動に後続し、前 記結合させる工程からの前記組み合わせ試料に由来する化合物の存在を検出し、 そして検出された化合物の第2の検出パターンを生成する前記一般的な検出方法 を使用する工程と、 前記第1の検出パターンには描写されているが前記第2の検出パターンには 描写されていない化合物を探すために、前記第1の検出パターンと前記第2の検 出パターンを比較する工程と、 複合生物物質の前記第1の試料に由来する化合物であって、前記結合する工 程からの前記組み合わせ試料に由来する化合物の中には存在しないものを分離す る工程と を備えることを特徴とする方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US850395P | 1995-12-11 | 1995-12-11 | |
US60/008,503 | 1995-12-11 | ||
US08/662,085 | 1996-06-12 | ||
US08/662,085 US5783397A (en) | 1995-12-11 | 1996-06-12 | Screening natural samples for new therapeutic compounds using capillary electrophoresis |
PCT/US1996/019779 WO1997022000A1 (en) | 1995-12-11 | 1996-12-10 | Screening natural samples for new therapeutic compounds using capillary electrophoresis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000502443A true JP2000502443A (ja) | 2000-02-29 |
JP3603267B2 JP3603267B2 (ja) | 2004-12-22 |
Family
ID=26678258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52219897A Expired - Fee Related JP3603267B2 (ja) | 1995-12-11 | 1996-12-10 | 毛管電気泳動を使用して新規の治療コンパウンド類のための天然物サンプルのスクリーニング |
Country Status (8)
Country | Link |
---|---|
US (1) | US5783397A (ja) |
EP (1) | EP0876609B1 (ja) |
JP (1) | JP3603267B2 (ja) |
CA (1) | CA2239418C (ja) |
DE (1) | DE69624942T2 (ja) |
DK (1) | DK0876609T3 (ja) |
ES (1) | ES2187685T3 (ja) |
WO (1) | WO1997022000A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006126039A (ja) * | 2004-10-29 | 2006-05-18 | National Institute Of Advanced Industrial & Technology | 細胞の分離、同定装置及び方法 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5942443A (en) * | 1996-06-28 | 1999-08-24 | Caliper Technologies Corporation | High throughput screening assay systems in microscale fluidic devices |
CN1173776C (zh) | 1996-06-28 | 2004-11-03 | 卡钳技术有限公司 | 在微规模流体性设备里的高通过量的筛选分析系统 |
US6528098B2 (en) * | 1996-10-22 | 2003-03-04 | Advanced Viral Research Corp. | Preparation of a therapeutic composition |
US6455323B1 (en) * | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
US7745142B2 (en) | 1997-09-15 | 2010-06-29 | Molecular Devices Corporation | Molecular modification assays |
US6299747B1 (en) * | 1997-12-17 | 2001-10-09 | Cetek Corporation | Capillary electrophoretic methods to detect new biologically active compounds in complex biological material |
CA2316290C (en) * | 1997-12-24 | 2004-11-23 | Cetek Corporation | Capillary electrophoretic method to detect target-binding ligands and to determine their relative affinities |
JP2004500541A (ja) * | 1998-07-10 | 2004-01-08 | セテク コーポレイション | 複合生化学サンプル中の強結合配位子の検出及び分析の方法 |
US6432651B1 (en) | 1998-07-10 | 2002-08-13 | Cetek Corporation | Method to detect and analyze tight-binding ligands in complex biological samples using capillary electrophoresis and mass spectrometry |
US6132685A (en) | 1998-08-10 | 2000-10-17 | Caliper Technologies Corporation | High throughput microfluidic systems and methods |
US20020010550A1 (en) | 1998-09-14 | 2002-01-24 | George M. Grass | Pharmacokinetic-based drug design tool and method |
WO2000043787A1 (en) * | 1999-01-26 | 2000-07-27 | Du Pont Pharmaceuticals Company | Electrophoretic assays to assess conformational changes of integrins induced by ligand binding |
US6329145B1 (en) * | 1999-02-09 | 2001-12-11 | Gilead Science, Inc. | Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand |
WO2000047999A1 (en) | 1999-02-12 | 2000-08-17 | Cetek Corporation | High throughput size-exclusive method of screening complex biological materials for affinity ligands |
US6306628B1 (en) | 1999-08-25 | 2001-10-23 | Ambergen, Incorporated | Methods for the detection, analysis and isolation of Nascent proteins |
US7217573B1 (en) * | 1999-10-05 | 2007-05-15 | Hitachi, Ltd. | Method of inspecting a DNA chip |
EP1360315A2 (en) | 2000-04-06 | 2003-11-12 | PHARMACIA & UPJOHN COMPANY | Antimicrobial methods and materials |
US7252932B1 (en) | 2000-08-23 | 2007-08-07 | Ambergen, Inc. | Methods for the detection, analysis and isolation of nascent proteins |
EP1720011A1 (en) | 2000-12-01 | 2006-11-08 | Cetek Corporation | High throughput capillary electrophoresis system |
US20030132117A1 (en) * | 2002-01-14 | 2003-07-17 | Andras Guttman | Thin film electrophoresis apparatus and method |
US20040266021A9 (en) * | 2001-01-26 | 2004-12-30 | Andras Guttman | Multicapillary fraction collection system and method |
US20030087321A1 (en) * | 2001-09-28 | 2003-05-08 | Tomich Che-Shen C. | Antimicrobial methods and materials |
US20050272089A1 (en) * | 2001-10-19 | 2005-12-08 | Mott John E | Critical genes and polypeptides of haemophilus influenzae and methods of use |
AU2003209054A1 (en) * | 2002-02-07 | 2003-09-02 | Discovery Genomics, Inc. | Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation and methods of use thereof |
JP4795688B2 (ja) * | 2002-10-09 | 2011-10-19 | ウオーターズ・テクノロジーズ・コーポレイシヨン | サンプル中の化合物を同定する方法および装置 |
US7672786B2 (en) | 2003-07-02 | 2010-03-02 | Sergey Krylov | Non-equilibrium capillary electrophoresis of equilibrium mixtures (NECEEM)—based methods for drug and diagnostic development |
JP2008542369A (ja) * | 2005-06-03 | 2008-11-27 | アドバンスト バイラル リサーチ コープ. | Avr118を用いて苦痛緩和医療を提供する方法 |
US7959861B2 (en) * | 2007-09-19 | 2011-06-14 | Stc.Unm | Integrated affinity microcolumns and affinity capillary electrophoresis |
KR101388539B1 (ko) | 2008-02-12 | 2014-04-23 | 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. | 색 검출기 |
US8319969B2 (en) | 2008-02-13 | 2012-11-27 | Hewlett-Packard Development Company, L.P. | Color detector having area scaled photodetectors |
BRPI0901112A2 (pt) * | 2009-03-12 | 2010-11-16 | Luiz Augusto Pinto | processo de produção de oligonucleotìdeos de alta afinidade e alta especificidade para moléculas orgánicas e inorgánicas |
DE112010002222B4 (de) | 2009-06-04 | 2024-01-25 | Leidos Innovations Technology, Inc. (n.d.Ges.d. Staates Delaware) | Mehr-Proben-Mikrofluidchip fur DNA-Analyse |
AU2011315951B2 (en) | 2010-10-15 | 2015-03-19 | Lockheed Martin Corporation | Micro fluidic optic design |
US9322054B2 (en) | 2012-02-22 | 2016-04-26 | Lockheed Martin Corporation | Microfluidic cartridge |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991006850A1 (en) * | 1989-11-06 | 1991-05-16 | Massachusetts Institute Of Technology | Affinity co-electrophoresis |
WO1992013972A1 (en) * | 1991-02-11 | 1992-08-20 | Thomas Jefferson University | Genetically engineered bacteria to identify and produce medically important agents |
JP3175941B2 (ja) * | 1991-03-28 | 2001-06-11 | パーセプティブ バイオシステムズ インコーポレイテッド | クロマトグラフ溶出液の減法に依るオンライン生成物確認方法及び装置 |
US5413686A (en) * | 1992-07-17 | 1995-05-09 | Beckman Instruments, Inc. | Multi-channel automated capillary electrophoresis analyzer |
US5348633A (en) * | 1993-01-22 | 1994-09-20 | Northeastern University | Method for quantitating trace amounts of an analyte in a sample by affinity capillary electrophoresis |
EP0681585A4 (en) * | 1993-01-28 | 1998-09-30 | Univ California | FACTORS ASSOCIATED TO TATA-BINDING PROTEINS, NUCLEIC ACIDS ENCODING TAFS AND METHODS FOR USE THEREOF. |
US5324401A (en) * | 1993-02-05 | 1994-06-28 | Iowa State University Research Foundation, Inc. | Multiplexed fluorescence detector system for capillary electrophoresis |
US5567282A (en) * | 1994-01-25 | 1996-10-22 | Wang; Hann-Ping | On-capillary electrophoretic immunosubtraction for classification and typing of M-proteins |
US5536382A (en) * | 1994-05-23 | 1996-07-16 | Advanced Molecular Systems, Inc. | Capillary electrophoresis assay method useful for the determination of constituents of a clinical sample |
US5431793A (en) * | 1994-07-29 | 1995-07-11 | Beckman Instruments, Inc. | Quantitative analysis of glycosylated hemoglobin by immunocappillary electrophoresis |
-
1996
- 1996-06-12 US US08/662,085 patent/US5783397A/en not_active Expired - Lifetime
- 1996-12-10 ES ES96944795T patent/ES2187685T3/es not_active Expired - Lifetime
- 1996-12-10 DK DK96944795T patent/DK0876609T3/da active
- 1996-12-10 CA CA002239418A patent/CA2239418C/en not_active Expired - Fee Related
- 1996-12-10 DE DE69624942T patent/DE69624942T2/de not_active Expired - Fee Related
- 1996-12-10 EP EP96944795A patent/EP0876609B1/en not_active Expired - Lifetime
- 1996-12-10 JP JP52219897A patent/JP3603267B2/ja not_active Expired - Fee Related
- 1996-12-10 WO PCT/US1996/019779 patent/WO1997022000A1/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006126039A (ja) * | 2004-10-29 | 2006-05-18 | National Institute Of Advanced Industrial & Technology | 細胞の分離、同定装置及び方法 |
JP4512745B2 (ja) * | 2004-10-29 | 2010-07-28 | 独立行政法人産業技術総合研究所 | 細胞の分離、同定装置及び方法 |
Also Published As
Publication number | Publication date |
---|---|
DE69624942D1 (de) | 2003-01-02 |
CA2239418A1 (en) | 1997-06-19 |
ES2187685T3 (es) | 2003-06-16 |
EP0876609B1 (en) | 2002-11-20 |
US5783397A (en) | 1998-07-21 |
WO1997022000A1 (en) | 1997-06-19 |
CA2239418C (en) | 2005-09-20 |
DE69624942T2 (de) | 2003-09-18 |
DK0876609T3 (da) | 2003-03-17 |
JP3603267B2 (ja) | 2004-12-22 |
EP0876609A1 (en) | 1998-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3603267B2 (ja) | 毛管電気泳動を使用して新規の治療コンパウンド類のための天然物サンプルのスクリーニング | |
WO1997022000A9 (en) | Screening natural samples for new therapeutic compounds using capillary electrophoresis | |
US7160735B2 (en) | Tagged microparticle compositions and methods | |
Peng et al. | Proteomics: the move to mixtures | |
JP3517241B2 (ja) | 生体高分子の適応度を評価するための方法および装置 | |
US8224582B2 (en) | Non-equilibrium capillary electrophoresis of equilibrium mixtures (NECEEM)-based methods for drug and diagnostic development | |
US5723031A (en) | Method for the analytical separation of viruses | |
US7179592B2 (en) | Size-exclusion-based extraction of affinity ligands and active compounds from natural samples | |
US20030235832A1 (en) | Multiplexed analysis by chromatographic separation of molecular tags | |
Tagliaro et al. | Recent advances in the applications of CE to forensic sciences (2005–2007) | |
Van Craenenbroeck et al. | Fluorescence correlation spectroscopy: molecular recognition at the single molecule level | |
CA2315051C (en) | Capillary electrophoretic methods to detect new biologically active compounds in complex biological material | |
AU775000B2 (en) | Methods of identifying compounds that bind to target species under isothermal denaturing conditions | |
JP2004500541A (ja) | 複合生化学サンプル中の強結合配位子の検出及び分析の方法 | |
EP1456657A1 (en) | Tagged microparticle compositions and methods | |
US20020061531A1 (en) | Detection of binding factors with fluorescence polarization | |
US20040175299A1 (en) | Microscale affinity purification system | |
JP2003502665A (ja) | 検出可能な競合リガンドを使用した、親和性リガンドのスクリーニングに適したキャピラリ電気泳動法 | |
WO2002082066A1 (en) | Concentration and identification of moderate-to-strong hits in natural products by capillary electrophoresis | |
Ruth | Government and Society: Translating trans fatty acid labeling | |
Harris | Research Profiles: The unexpected gas-phase Raman spectrometer | |
Smith et al. | Research Profiles: SERRS sensitivity gains with shrinking flow | |
Castro et al. | Single-molecule electrophoresis: applications to biomolecular detection | |
AU2002340431A1 (en) | Tagged microparticle compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040316 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040615 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040831 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040917 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |